Upload
pedro-blakeley
View
220
Download
1
Embed Size (px)
Citation preview
Selection of malaria treatments& diagnostics
Presentation by Rémy ProhomRBM Partnership Secretariat, Malaria Medicines & Supplies Services
Anglophone PSM Workshop, Nairobi Kenya, 20-24February 2006
TreatmentsSelection of malaria treatments & diagnostics
Artemisin-based combination therapies have proven to be the most effective.
ISSUE:
• API of artemisinin cannot be produced yet by synthesis
• ACTs manufacturing rely then on agricultural raw material production
• Joint tender WHO-UNICEF to manufacturers of ACTs
• Long Term Agreement to ensure low and stable price with selected manufacturers
• WHO-UNICEF-IAPSO can order Coartem@ at cost price for public health sector
• Partners advocacy to strengthen production and bring more manufacturers in the loop
Practical solutions
Combination therapies recommended by WHO
WHO Technical Consultation on “Antimalarial Combination Therapy” – April 2001
• Artesunate + amodiaquine
• Artemether/Lumefantrine
• Artesunate + SP
• Artesunate + mefloquine
FDC
ACTs
Response to increasing resistance
Artemether/Lumefantrine
Treatment of acute uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum in areas with significant multidrug resistance.
Model Model Description Units
box Unit
Price
Coartem® (30X24) Artemether 20 mg + Lumefantrine 120 mg, tablets (6x4) treatment for patients over 35 kg
30 $2.4
Coartem® (30X18) Artemether 20 mg + Lumefantrine 120 mg, tablets (6x3) treatment for patients from 25 to 34 kg
30 $1.9
Coartem® (30X12) Artemether 20 mg + Lumefantrine 120 mg, tablets (6x2) treatment for patients from 15 to 24 kg
30 $1.4
Coartem® (30X6) Artemether 20 mg +Lumefantrine 120 mg, tablets (6) treatment for patients from 5 to 14 kg.
30 $0.9
Artemether/Lumefantrine
Novartis Pharma AG
Treatment of acute uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum in areas with significant drug resistance to Chloroquine or Sulfadoxine-Pyrimethamine.
Artesunate+Amodiaquine
3 Manufacturers currently selected:
– CIPLA– IPCA– SANOFI AVENTIS
Artesunate+Amodiaquine
Average prices for AS+AQ:
3+3 $0.50
6+6 $0.85
12+12 $1.51
Artesunate+Amodiaquine
CIPLA
Model Model Descriptionunits/box
Falcimon kit Artesunate 50 mg+Amodiaquine 153mg (base) tablets (3+3) in co-blister, combined
treatment for children from 1 to 7 years old (10-20 kg), individually packed.
1
Falcimon kit Artesunate 50 mg+Amodiaquine 153mg (base) tablets (6+6) in co-blister, combined
treatment for children from 7 to 13 years old (21-40 kg), individually packed.
1
Falcimon kit Artesunate 50 mg+Amodiaquine 153mg (base) tablets (12+12) in co-blister, combined
treatment for patients over 13 years old (over 40kg), individually packed.
1
Artesunate+Amodiaquine
IPCA PHARMACEUTICALS
Model Descriptionunits/box
Artesunate 50 mg+Amodiaquine 153mg (base) tablets (3+3) in co-blister, combined treatment
for children from 1 to 7 years old (10-20 kg)
10 and 100
Artesunate 50 mg+Amodiaquine 153mg (base) tablets (6+6) in co-blister, combined treatment for children from 7 to 13 years old (21-40 kg)
10 and 100
Artesunate 50 mg+Amodiaquine 153mg (base) tablets (12+12) in co-blister, combined treatment
for patients over 13 years old (over 40kg)
10 and 100
Artesunate+Amodiaquine
Model Model Description units/box
Arsucam® Artesunate 50 mg+Amodiaquine 153mg (base) tablets (3+3) in co-blister, combined treatment
for children from 1 to 6 years old (10-20 kg)
25
Arsucam® Artesunate 50 mg+Amodiaquine 153mg (base) tablets (6+6) in co-blister, combined treatment for children from 7 to 13 years old (21-40 kg)
25
Arsucam®adult
Artesunate 50 mg+Amodiaquine 153mg (base) tablets (12+12) in co-blister, combined
treatment for patients over 13 years old (over 40kg)
25
Artesunate+Amodiaquine
SANOFI-AVENTIS
Treatment of acute uncomplicated malaria due to Plasmodium falciparum in areas where resistance to Sulfadoxine-Pyrimethamine is low (i.e. where the 28-day cure exceeds 80%).
Artesunate+Sulfadoxine/Pyrimethamine
Model Model Description units/boxUnit
price
Artecospe for children
Artesunate 50mg + Sulfadoxine/Pyrimethamine 500/25mg tablets (6+2) in co-blister, combined
treatment for paediatric patients from 5 months to 13 years old (or under 40 kg),
individually packed.
1 $0.79
Artecospe for adults
Artesunate 100mg + Sulfadoxine/Pyrimethamine 500/25mg tablets (6+3) in co-blister, combined
treatment for patients over 14 years old and body weight over 40kg, individually
packed.
1 $1.41
Artesunate+Sulfadoxine/Pyrimethamine
GUILIN
• Until now both independent drug WHO GMP approved were purchased separately and given together to the patient;
• A co-blister formulation has just been GMP approved and is available on the market, but at a much higher price.
Artesunate+Mefloquine
Lead time delivery
• Address a request to the manufacturer (or procurement agent) for each and every order for any ACT and get a written answer on the delivery time for your specific order.
• Lead time may vary depending of many factors (production site, quantities, packaging, volume and destination) and therefore should be planned much ahead.
Remember about ACTs…
• Short shelf life (24 months)
• Increased costs
• Longer lead time for deliveries
• Challenging implementation
Rapid Diagnostic TestsSelection of malaria treatments & diagnostics
Considerations for choosing an RDT include:
• Plasmodium species to be detected (P. falciparum only, or panspecific)• Shelf -life and temperature stability in intended conditions of storage
and use• Ease of use, including format of the test (e.g. cassette, dipstick, card)• Requirement for post-treatment testing of patients• Cost (including transport, training, and quality control)• Sensitivity
Good quality assurance processes after purchaseare likely to be of greater importance.
Choice of RDTs
Quality assurance
Quality assurance system to sustain the reliability of RDTs
Transport & stockMonitoring & temperature
control
ManufacturerGood manufacturing
practices/control
LaboratoryNat/RegionalBatch control
District/remote areas
sensitivity check
Final userTraining & supervision
Procurement issues
• Real-time temperature stability data on the product, and accelerated data on the purchased lot
• Evidence of successful operational use, or good quality field data on the product
• Long-term viability of manufacturer (to ensure continuity of supply)
• Evidence of Good Manufacturing Practice /ISO certification (ISO13485:2003 is specific for quality management systems for medical devices)
…/…
Procurement issues
• Availability of product support
• Provision of sample products for assessment and testing for ease of use
• Agreement for replacement of products which fail agreed quality control procedures (see above)
• Box sizes appropriate to the rate of use of tests in the intended area, to minimize storage time in poor conditions and reduce the need to split boxes.
How to contact us…
Malaria Medicines & Supply Services (MMSS)Roll Back Malaria Partnership Secretariat
Website: http://rbm.who.int/mmss/
Mr Remy Prohom
Technical Officer
ACTs and RDTs related issues
Tel: +41 (0)22 791 2679
E-mail: [email protected]